PCVX at a glance
Vaxcyte, Inc. (PCVX, SEC CIK 1649094) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on October 5, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 33 institutional investment managers tracked by SignalX reported holding Vaxcyte, Inc. (PCVX) shares worth $3.8 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Wassil Jim on October 1, 2026 of 95 shares at $57.09 per share.
- In the last 90 days, PCVX insiders reported 0 open-market purchases ($0) and 25 open-market sales ($4.1M) on Form 4, a net sale of $4.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 25 sells
- Net −$4.1M
- 13F holders
- 33 funds
- $3.8B · −2 vs prior quarter
- Latest 8-K
- Sep 3, 2026
- Item 5.02 · Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Development and commercialization of proprietary pneumococcal conjugate vaccines
- New manufacturing agreement with Lonza Ltd effective January 2026 for development and commercial supply of vaccine components
- Strategic move to secure long-term manufacturing capacity with fees in mid- to high-eight-figures Swiss Francs annually through 2038 plus renewals
- License received from Lonza: perpetual, irrevocable, royalty-free rights to use Lonza’s intellectual property related to product and manufacturing process
- Contract includes termination rights with termination fees in low-eight-figures Swiss Francs, ensuring operational flexibility and risk mitigation
Risk Factors
- Cybersecurity breach risk with potential regulatory fines, investigations, operational disruptions, and reputational harm
- SVP IT with 30+ years experience leads cybersecurity risk management and incident response
- Cybersecurity incident escalation to President and CFO, with audit committee oversight and quarterly reporting
Management Discussion & Analysis
- No revenue generated in FY 2026 as Vaxcyte is clinical-stage; net losses $766.6M in 2025 vs $463.9M in 2024 vs $402.3M in 2023
- Operating losses increased due to advancing clinical trials and manufacturing scale-up; cash, equivalents, investments $2.44B as of Dec 31, 2025
- Best performing pipeline: VAX-31 Phase 3 adult PCV program initiated with ~3,560 adults dosed; FDA breakthrough therapy designation expanded to pneumonia prevention
- Capital raise: February 2026 public offering gross proceeds $632.5M from 12.65M shares at $50 each
- Forward outlook: Phase 3 data awaited late 2026 (adult) and first half 2027 (infant); planning BLA submission post Phase 3; risks include development timelines and regulatory approvals
AI summary of the PCVX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no approved products or commercial sales
- Net loss $284.3M for three months ended June 30, 2026
- Cash, equivalents and investments $2.5B; sufficient through at least 12 months
- VAX-31 Phase 3 trials fully enrolled; 6,191 adults dosed, including approximately 3,500 receiving VAX-31
- Topline VAX-31 OPUS-1 data expected fourth quarter 2026; OPUS-2 and OPUS-3 data expected first half 2027
Risk Factors
- No explicit new risk factor identified; filing reiterates previously described development, regulatory, and financing risks
- Updated regulatory risk: FDA may challenge VAX-31’s Phase 3 CMC strategy, delaying approval and increasing costs
- Financial risk: $2.5 billion cash, equivalents, and investments fund operations for at least 12 months from filing
- Financial performance risk: $604.9 million six-month net loss and $2.8 billion accumulated deficit as of June 30, 2026
- Operational risk: manufacturing-process changes or scale-up failures could delay VAX-31, VAX-24, or other candidates
AI summary of the PCVX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- David McAvoy appointed Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary effective August 31, 2026
- Mikhail Eydelman remains Senior Vice President and General Counsel
Item 7.01: Regulation FD Disclosure
- Appointment of Chief Medical Officer and Chief Legal Officer, signaling leadership expansion
- Narrowed timing guidance for VAX-31 OPUS-1 topline data, improving visibility around the clinical readout
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release issued August 5, 2026
AI summaries of PCVX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PCVX
Don't miss the next PCVX filing
- Alerts as it files. A push when PCVX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PCVX, by share count.
- Ask anything. An AI agent that reads every PCVX filing and answers with sources.
PCVX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Wassil Jim | Sell | Oct 1, 2026 | 95 | $57.09 |
| Wassil Jim | M | Oct 1, 2026 | 2,250 | $5.35 |
| Wassil Jim | M | Oct 1, 2026 | 2,250 | - |
| Wassil Jim | Sell | Oct 1, 2026 | 2,155 | $56.65 |
| Wassil Jim | Sell | Sep 9, 2026 | 1,334 | $59.52 |
| Cowan Elvia | F | Sep 8, 2026 | 1,327 | $60.36 |
| Dhaliwal Harpreet S. | F | Sep 8, 2026 | 7,651 | $60.36 |
| PICKERING GRANT | F | Sep 8, 2026 | 17,056 | $60.36 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$468.0M | -$569.5M | -$923.7M |
| Net Income | -$402.3M | -$463.9M | -$766.6M |
| Balance Sheet | |||
| Total Assets | - | $3.5B | $3.0B |
| Equity | $1.2B | $3.3B | $2.7B |
| ROE | -32.4% | -14.0% | -28.5% |
| Per Share | |||
| EPS | $-4.14 | $-3.80 | $-5.63 |
| Cash Flow | |||
| Operating CF | -$296.8M | -$452.6M | -$655.6M |
| CapEx | $16.1M | $22.4M | $13.7M |
Source: XBRL data in Vaxcyte, Inc. (PCVX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate PCVX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 33 | $3.83B |
| Q1 2026 | 35 | $3.32B |
| Q4 2025 | 27 | $2.47B |
| Q3 2025 | 28 | $2.00B |
| Q2 2025 | 28 | $1.85B |
| Q1 2025 | 25 | $1.62B |
| Q4 2024 | 22 | $3.14B |
| Q3 2024 | 18 | $1.19B |
- FMR LLC (Fidelity)+4.36M (+26%)
- T. Rowe Price Group+2.01M (+206%)
- BlackRock+1.10M (+10%)
- State Street Corp+911.2K (+21%)
- Dimensional Fund Advisors+819.0K (+218%)
- D.E. Shaw & Co−963.4K (-34%)
- Millennium Management−157.1K (-53%)
- Bank of America Corp−138.0K (-11%)
- Renaissance Technologies LLC−35.1K (-64%)
- Prudential Financial−17.8K (-30%)
- Baupost Group−800.0K
- Blackstone Group−4.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 216 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PCVX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 5, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 8-K | Sep 3, 2026 | - | Analysis | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 16, 2026 | - | - | - |
| 8-K | Jul 15, 2026 | - | Analysis | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
PCVX SEC filings: frequently asked questions
Are PCVX insiders buying or selling?
In the last 90 days, Vaxcyte, Inc. (PCVX) officers, directors and 10% owners reported no open-market purchases and 25 open-market sales worth $4.1 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold PCVX stock?
As of June 30, 2026, the largest Vaxcyte, Inc. (PCVX) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($1.2 billion), BlackRock ($701.5 million), Vanguard Portfolio Management LLC ($383.3 million), Vanguard Capital Management LLC ($369.0 million), State Street Corp ($311.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in PCVX's latest 10-K?
In the 10-K filed February 24, 2026, Vaxcyte, Inc. (PCVX) flagged: Cybersecurity breach risk with potential regulatory fines, investigations, operational disruptions, and reputational harm. SVP IT with 30+ years experience leads cybersecurity risk management and incident response. (AI summary of the Risk Factors section.)
What did PCVX report in its latest 8-K?
Vaxcyte, Inc. (PCVX) filed an 8-K on September 3, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers) and Item 7.01 (Regulation FD Disclosure). David McAvoy appointed Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary effective August 31, 2026.
What are the latest PCVX SEC filings?
Vaxcyte, Inc. (PCVX) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on October 5, 2026 and a Form 4 insider filing on October 2, 2026.
What is PCVX's SEC CIK number?
Vaxcyte, Inc. (PCVX)'s SEC Central Index Key (CIK) is 1649094. EDGAR lists every PCVX filing under that number.
Ask anything about PCVX
The research agent reads PCVX's filings, financials, insider trades and 13F holders, then answers with sources.